Published on 5 May 2024 on Simply Wall St. via Yahoo Finance
Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest...
Last week, you might have seen that Puma Biotechnology, Inc. (NASDAQ:PBYI) released its first-quarter result to the market. The early response was not positive, with shares down 3.2% to US$4.86 in the past week. It looks like weak result overall, with ongoing losses and revenues of US$44m falling short of analyst predictions. The losses were a relative bright spot though, with a per-share (statutory) loss of US$0.10 being 54% smaller than what the analysts had presumed. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
See our latest analysis for Puma Biotechnology
